Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Clene’s nanocrystal breakthrough is exciting—decoding its SEC paperwork is not. Each 10-K details millions in R&D for CNM-Au8, every 8-K flags trial readouts, and Form 4 insider trades hint at executive confidence. Finding those nuggets across hundreds of pages is the real challenge.
Stock Titan solves that problem. Our AI-powered summaries break down Clene SEC filings explained simply, highlighting cash runway, NIH grant inflows, and milestone payments in seconds. Whether you search "How to read Clene’s 10-K annual report" or "Where can I find Clene’s quarterly earnings report 10-Q filing?", you land on real-time documents the moment they post to EDGAR—already analyzed.
Here’s what you’ll uncover faster:
- 10-Q & 10-K: R&D spend, liquidity outlook, and nanocrystal manufacturing costs—Clene annual report 10-K simplified.
- Form 4: Clene insider trading Form 4 transactions and executive stock moves, delivered as "Clene Form 4 insider transactions real-time" alerts.
- 8-K: Clinical data drops and financing updates—Clene 8-K material events explained.
- DEF 14A proxy: Clene proxy statement executive compensation and milestone-based pay structures.
Stop skimming PDFs and start asking bigger questions: "understanding Clene SEC documents with AI" or "Clene earnings report filing analysis." Our platform turns complex biotech disclosure into clear, actionable insight so you can decide—quickly—whether Clene’s next catalyst merits attention.
Clene Inc. has an ongoing equity distribution agreement with Canaccord Genuity LLC dated April 28, 2025, authorizing offers and sales of up to $25,000,000 of common stock. Through this program the company previously sold common stock totaling approximately $3,706,213. On September 5, 2025 Clene filed a prospectus supplement adding $6,280,000 of additional shares available for sale under the agreement. The legal opinion from Holland & Knight LLP regarding the validity of the shares is filed as Exhibit 5.1 and is incorporated by reference.
Clene Inc. (CLNN) insider sale reported. General Resonance LLC reported a sale of 3,401 shares of Clene common stock on 08/21/2025 at a price of $5.34 per share, leaving beneficial ownership of 704,591 shares. The Form 4 was filed by one reporting person and signed by Heidi Ley.
Clene Inc. (CLNN) filed a Form 4 disclosing that director Vallerie McLaughlin was granted a stock option to buy 4,092 shares of common stock. The option has an exercise price of $3.60 per share, vests immediately, and covers 4,092 underlying shares. The option grant is exercisable through an expiration date of 08/13/2035. The transaction date reported is 08/14/2025. The filing indicates the Form 4 was submitted by one reporting person and was signed under power of attorney.
Clene Inc. (CLNN) reported a Section 16 Form 4 disclosing that director David J. Matlin was granted a stock option on 08/14/2025 for 7,255 shares of common stock under the companys Amended 2020 Stock Plan. The option has an exercise price of $3.60 per share, vests immediately upon grant, and is exercisable through an expiration date of 08/13/2035. Following the grant, Mr. Matlin beneficially owns 7,255 underlying shares via this option, held in a direct ownership form. The Form 4 was filed by one reporting person and signed via POA.
Clene Inc. (CLNN) director Matthew Kiernan was granted a stock option on 08/14/2025 for 3,720 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The option vests immediately upon grant, is exercisable now, and expires on 08/13/2035. Following the grant, the reporting person beneficially owns 3,720 shares via direct ownership. The Form 4 was signed by a power of attorney, Jerome T. Miraglia, on 08/15/2025.
Clene Inc. director Alison Mosca was granted a stock option for 5,674 shares of common stock under the Clene Inc. Amended 2020 Stock Plan with an exercise price of $3.60 per share. The option was granted on 08/14/2025, vests immediately upon grant, is exercisable through 08/13/2035, and, if exercised, represents 5,674 shares of common stock. The Form 4 was signed via power of attorney on 08/15/2025.
Clene Inc. insider grant: Director Shalom Jacobovitz was granted a non-qualified stock option for 5,534 shares of Clene Inc. common stock on 08/14/2025 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The option vests immediately upon grant and is exercisable through 08/13/2035. Following the grant, the reporting person beneficially owns 5,534 underlying shares and exercised price per share for reporting is shown as $0 (reflecting the reporting field for shares beneficially owned). The Form 4 was signed by a POA on 08/15/2025.
Clene Inc. (CLNN) reported a Section 16 Form 4 showing that director Jonathon Gay was granted a stock option on 08/14/2025 for 4,790 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The filing states the options vest immediately upon grant.
The derivative instrument lists an expiration (or date referenced) of 08/13/2035. The Form 4 was signed by a power of attorney, Jerome T. Miraglia, on 08/15/2025. The report shows the acquisition was an option grant and indicates the number of underlying shares and exercise price but does not disclose total company holdings or percentage ownership after the grant.
FAQ
What is the current stock price of Clene (CLNN)?
What is the market cap of Clene (CLNN)?
